MAX DELBRUECK CENTRUM FUER MOLEKULARE MEDIZIN IN DER HELMHOLTZ-GEMEINSCHAFT (MDC)

Their core work

MDC is a major German research institute in Berlin specializing in molecular medicine — understanding the molecular basis of human disease to develop better diagnostics and therapies. Their core strengths span cancer biology, cardiovascular genetics, neuroscience, and sensory biology, with significant capabilities in advanced biomedical imaging (particularly ultrahigh-field MRI). As a Helmholtz Association center, they bridge fundamental molecular research with translational medicine, training the next generation of biomedical researchers through extensive Marie Curie and ERC-funded programs.

What they specialise in

How they've shifted over time

In the early H2020 period (2015–2018), MDC focused broadly on fundamental molecular biology — cancer mechanisms (DNA repair, B-cell biology), metabolic disorders, brain disease, and doctoral training networks in biomedicine. From 2019 onward, the portfolio sharpened toward translational themes: cardiovascular genetics (CodingHeart), sensory mechanotransduction (SENSATIONAL TETHERS), GPCR-based drug discovery (ONCORNET2.0), and advanced imaging technologies (ThermalMR, sodium MRI). There is a clear shift from basic discovery toward disease-specific translational research with stronger imaging and genomics infrastructure components.

MDC is moving from broad molecular discovery toward precision medicine applications — combining advanced imaging, single-cell genomics, and GPCR biology to develop targeted diagnostics and therapies, particularly in cardiovascular and sensory diseases.

How they like to work

MDC overwhelmingly leads its projects — coordinating 25 of 40 H2020 grants (63%), driven by a high concentration of prestigious ERC Starting and Advanced Grants that are PI-led by definition. With 180 unique partners across 27 countries, they function as a hub rather than a loyal-partner organization, assembling project-specific consortia. This means they are experienced coordinators comfortable managing international teams, but prospective partners should expect MDC to set the scientific agenda rather than follow someone else's.

MDC has collaborated with 180 distinct partners across 27 countries, making them one of the more broadly connected biomedical research institutes in Europe. Their network spans the full EU research landscape with no obvious geographic concentration beyond expected strong ties to other German and Western European institutions.

What sets them apart

MDC combines three capabilities rarely found together: deep molecular biology expertise, an advanced ultrahigh-field MRI imaging program, and strong genomics infrastructure — all under one roof in Berlin. Their exceptional ERC success rate (11 grants across Starting and Advanced categories) signals world-class individual researchers, not just institutional volume. For consortium builders, MDC offers a credible coordinator with proven management of large EU grants and the scientific weight to anchor a health or life-science proposal.

Highlights from their portfolio

• SENSATIONAL TETHERS
  Largest single grant (EUR 2.5M ERC Advanced) investigating the molecular machinery of touch — a distinctive research niche combining mechanobiology with sensory neuroscience.
• ThermalMR
  EUR 2M ERC grant developing a new MRI instrument that maps temperature in living tissue — an unusual intersection of physics, engineering, and biomedicine.
• iGBMavatars
  EUR 1.5M ERC grant using CRISPR screens and neural stem cells to build avatar tumor models for glioblastoma — directly translational cancer research with drug resistance focus.